Steven Stein, MD
The combination of itacitinib and corticosteroids did not induce a statistically significant improvement in overall response rate (ORR) at day 28 compared with placebo plus corticosteroids in patients with treatment-naïve acute graft-versus-host disease (aGVHD), missing the primary endpoint of the phase III GRAVITAS-301 trial (NCT03139604).1
- Incyte announces results of phase 3 study of itacitinib in patients with treatment-naïve acute graft-versus-host disease [news release]. Wilmington, DE: Incyte Corporation; January 2, 2020. bit.ly/39LJVHq. Accessed January 2, 2020.
- Pratta MA, Liu H, Owens S, et al. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft versus host disease. Blood. 2019;134(suppl_1):3279. doi: 10.1182/blood-2019-124069.
... to read the full story